Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma

NCT03671018 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT03671018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03671018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 25, 2018
Completion date
July 20, 2025
Enrollment
422 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin lymphoma